Kainos Co., Ltd.

DOMS-IATRON Co., Ltd. (currently Kainos) was established with a capital stock of 30,000,000 yen as a developer of new products in the health care industry.

Established: May 1, 1975.

Changed its name to Kainos Laboratories, Inc.

Name changed to Kainos Laboratories, Inc.

Released the world’s first enzyme-based serum transaminase measurement reagent kit.

Released the world's first enzyme-based serum aspartate transaminase measurement kit.

Formed a technical tie-up with Mitsui Pharmaceutical Industry Co. (Currently Bayer Yakuhin,Ltd.) on enzyme immunoassay method (EIA).

Entered into a technology partnership with Mitsui Pharmaceutical (now Bayer Pharmaceuticals) regarding enzyme immunoassay (EIA).

Entered into a technical tie-up agreement with Hitachi Chemical Co., Ltd.(Currently Hitachi Chemical Diagnostics Systems Co., Ltd.) on reagents for clinical analysis equipment.

Entered into a technology partnership with Hitachi Chemical (now Hitachi Chemical Diagnostics Systems) regarding clinical analytical reagents.

Entered into a sales agreement for blood transfusion diagnostics products with GAMMA BIOLOGICALS, Inc (USA)

Signed a sales agreement with the U.S. company GAMMA BIOLOGICALS for blood transfusion diagnostic products.

Entered into a sales agreement for blood transfusion diagnostics products with GAMMA BIOLOGICALS, Inc (USA).

Released an enzyme-based creatinine measurement reagent kit.

Released an enzyme-based creatinine measurement reagent.

Entered into a technical tie-up agreement with Nippon Kayaku Co., Ltd. on clinical examination reagents.

Entered into a technology partnership with Nihon Kakyaku regarding clinical test reagents.

Entered into a technical tie-up agreement with Kirin Beer Co., Ltd. (Currently Kyowa Kirin Co., Ltd.) on clinical examination reagents.

Entered into a technology partnership with Kirin Brewery (now Kirin Company) regarding clinical test reagents.

Moved production to Kasama Factory, and began production of biochemical and immunoserological reagents.

Moved production to the Kasama factory and began manufacturing biochemical and immunohematology reagents.

Entered into a technical tie-up agreement with Asahi Chemical Industry Co., Ltd. (Currently Asahi Kasei Pharma Corporation) on clinical examination reagents.

Entered into a technology partnership with Asahi Chemical Industry (now Asahi Kasei Pharma) regarding clinical test reagents.

Moved the Head Office to Hongo, Bunkyo-ku, Tokyo.

Relocated headquarters to Hongo, Tokyo.

Listed on JASDAQ.

Listed on JASDAQ.

Acquired ISO 9001 certification, an international standard for quality assurance.

Obtained ISO 9001 certification.

Entered into the licence agreement of NASBA Patents with Organon Teknika B. V.(Ownership of the “NASBA Gene Amplification” patent has been transferred from Organon Teknika B.V. to bioMerieux.)

Signed a licensing agreement for NASBA patents with Organon Teknika B.V. (ownership transferred to bioMerieux).

Entered into a distributorship agreement for genetic products with bioMerieux Japan.

Entered into a distribution agreement for gene-related products with bioMerieux Japan.

Launched marketing of an influenza detection reagent “Statmark™ Influenza A/B” that had been jointly developed by Nichirei Corporation (currently Nichirei Bioscience Inc,) and Kainos.

Commenced sales of the Statmark™ Influenza A/B detection kit jointly developed with Nichirei.

Created Kainos BB, Co. Ltd. by spinning out Kainos’ Blood Banking business (in June 2005) then changed the name of the spun out company to Immucor-Kainos, Inc. through a joint venture agreement established as a part of the ongoing collaborative effort between Immucor, Inc. and Kainos.

Divested the blood bank business and established Kainos BB, Co. Ltd., later renamed Immucor-Kainos, Inc.

Acquired ISO 13485 certification, an international standard for quality assurance of in vitro medical equipment.

Obtained ISO 13485 certification.

Acquired ISO 13485 certification, an international standard for quality assurance of in vitro medical equipment.

Reobtained ISO 13485 certification.

Introduction of the Kainos Executive Office System. Established Compliance Center.

Implemented the Kainos Executive Office System and established a Compliance Center.

Kainos-Immucor, Inc.’s (currently K. K. Immucor) stocks were transferred to Immucor, Inc.

Shares of Kainos-Immucor, Inc. were transferred to Immucor, Inc.

Entered into a distributorship agreement for blood transfusion diagnostics products with Grifols SA.

Entered into a distribution agreement for blood transfusion diagnostic products with Grifols SA.

Insurance coverage granted to the assays respectively measuring two fractions of blood carnitine using blood carmitine measuring reagents based on the enzyme cycling method.

Obtained insurance coverage for a reagent measuring two fractions of plasma carnitine using an enzymatic cycle method.

Insurance coverage granted to the diagnostic drug based on an ADAMTS13 activity measurement reagent for the thrombotic thrombocytopenic purpura.

Obtained insurance coverage for a diagnostic reagent measuring ADAMTS13 activity.

Signed a share transfer agreement with Asahi Kasei Pharma, strengthening mutual business relations.

Concluded a share transfer agreement with Asahi Kasei Pharma Corporation to further enhance the mutual business relationship.

Capital tie-up with Gene Therapy Research Institution Co.,Ltd. by accepting a part of its third-party allotment of shares.

Implemented a capital partnership with Gene Therapy Research Institution and accepted a third-party allotment of shares.

Concluded a capital and business tie-up with Sysmex Corporation to further enhance the mutual business relationship.

Entered into a capital and business partnership with Sysmex Corporation.

Delisted from the Tokyo Stock Exchange Standard Market. Became a wholly owned subsidiary of Denka Co., Ltd.